## Note
nid: 1495998808961
model: AnKingOverhaul
tags: #AK_Original_Decks::Step_1::Zanki_Pharmacology, #AK_Step1_v11::!FLAG_THESE_CARDS::!DELETE, #AK_Step1_v11::#FirstAid::10_Hematology_Oncology::05_Pharm::17_Irinotecan_Topotecan, #AK_Step1_v11::#OME_banner, #AK_Step1_v11::#Physeo::09_Pharm::17_Hem/Onc_Pharm::Etoposide_Teniposide_Irinotecan_Topotecan, #AK_Step1_v11::#Pixorize::02_Biochem::22_Onc_Drugs::15_Irinotecan,_Topotecan, #AK_Step1_v11::#Pixorize::03_Pharm::11_Oncology::Etoposide,_Teniposide, #AK_Step1_v11::#Pixorize::03_Pharm::11_Oncology::Irinotecan,_Topotecan, #AK_Step1_v11::#SketchyPharm::08_Antineoplastics::02_Dna_&_Cellular_Division::04_Etoposide,_teniposide,_topotecan,_irinotecan::zanki_extra, #AK_Step1_v11::^Other::^EXPN, #AK_Step1_v11::^Other::^HighYield::4-LowerYield
markdown: false

### Text
<div>
  <b>Topoisomerase I</b> inhibitors commonly manifest with side
  effects of {{c1::<b>gastrointestinal</b>}} distress and
  <b>myelosuppression</b>
</div>

### Extra
<div>
  <i>A general rule for chemotherapeutics is that they will have
  side effects at <b>rapidly dividing cell</b> populations (ex Gut
  Mucosa)</i>
</div><i><img src="paste-215650307932161.jpg"></i>
<div>
  <i>Those with two copies of the <b>UGT1A1*28 gene variant</b> are
  at higher risk for side effects with <b>Irinotecan</b></i>
</div>

### Lecture Notes


### Missed Questions


### Pathoma


### Boards and Beyond


### First Aid
<img src="paste-171519518965763.jpg">

### Sketchy
<img src="paste-376995049373697.jpg" class="resizer"><img src=
"paste-6b01b2ac4f9c03fde9bf00e33779f280a3ba4881.png" class=
"resizer">

### Pixorize


### Physeo


### OME
<div class="ome-widget">
  <a href="https://onlinemeded.org?ref=anki"><img src=
  "_OME_AnkiFlashcards_General_3.png"></a>
</div>

### Additional Resources


### One by one

